News & Events
News & Events
July 18, 2023
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.
June 13, 2023
C-Path’s PSTC Receives Positive FDA Response for Drug-Induced Pancreatic Injury Biomarkers
C-Path today announced that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) in the U.S. Food and Drug Administration (FDA) issued a Biomarker Letter of Support (LOS) for four pancreatic injury safety biomarkers identified and evaluated by C-Path’s Predictive Safety Testing Consortium (PSTC)’s Pancreatic Injury Working Group (PIWG).
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
November 10, 2021
C-Path Promotes Nick King and Emily Turner to Executive Directors
Critical Path Institute (C-Path) today announced it has promoted Nicholas King, M.S., as Executive Director of its Predictive Safety Testing Consortium (PSTC) and Emily Turner, Ph.D., as Executive Director of the Huntington’s Disease Regulatory Science Consortium (HD-RSC).